Paris City Council Awards €31.5M Vaccine Framework Contracts to Multiple Winners

The City of Paris has awarded a series of framework contracts for the supply and delivery of vaccines and tuberculin tests, with a total maximum value of €31.5 million. The procurement is divided into 32 lots covering a wide range of vaccines including chikungunya, dengue, diphtheria, tetanus, polio, hepatitis, HPV, meningitis, pneumococcal, rabies, influenza, and COVID-19-related vaccines. Multiple pharmaceutical companies including Sanofi, GSK, MSD, Pfizer, Bavarian Nordic, and Valneva have been awarded contracts.

Introduction

The City of Paris, through its Direction des Finances et des Achats (DFA) - Sous-direction des Achats (SDA), has conducted an open procedure for the procurement of vaccines and tuberculin tests. The procurement covers 32 lots, each representing a specific vaccine or test, with a total maximum value of €31,521,600.

The framework agreements are multi-supplier, unit-price agreements executed via purchase orders, with no minimum commitment and a maximum value per lot. The contracts run for an initial 12-month period, with the option for tacit renewal up to three times, for a maximum total duration of 48 months.

Major pharmaceutical companies including Sanofi Winthrop Industrie, Laboratoire GlaxoSmithKline, MSD France, Pfizer, Bavarian Nordic France, Valneva France, and Imaxio have been awarded contracts across various lots.

Why This Contract Matters

This contract ensures that the City of Paris has a reliable and diverse supply of vaccines and tuberculin tests for its public health programmes.

This contract matters because it:

• Supports public health: Ensures vaccine availability for Paris residents
• Significant value: Total maximum value of €31,521,600
• Comprehensive scope: 32 lots covering 31 vaccines and tuberculin tests
• Long-term commitment: Up to 4 years (12 months + 3 renewals)
• Multiple suppliers: Contracts awarded to leading pharmaceutical companies
• Quality focus: 30% weighting on quality
• Price competition: 70% weighting on price

Contract Timeline

• Previous notice: 166850-2026
• Contract concluded: 11 August 2026
• Initial duration: 12 months
• Maximum renewals: 3 (tacit renewal)
• Maximum total duration: 48 months
• Notice published: 26 August 2026 (OJ S 164/2026)

Contract Overview

The City of Paris conducted an open procedure under the standard regime, governed by EU Directive 2014/24/EU.

Key features include:

• 32 lots: Covering a wide range of vaccines and tuberculin tests
• Total maximum value: €31,521,600
• Framework type: Multi-supplier framework agreements with unit prices, executed via purchase orders
• No minimum commitment: Each lot has no minimum purchase obligation
• Duration: 12 months initial, with up to 3 tacit renewals (max 48 months)
• Evaluation: Price (70%), Quality (30%)
• Winners: Multiple pharmaceutical companies
• No subcontracting declared
• No EU funding

Key Contract Details

Detail	Information
Contracting authority	VILLE de PARIS - DFA - SDA (City of Paris - Directorate of Finance and Procurement)
Contract title	Fourniture et livraison de vaccins et tests tuberculiniques
Main CPV	33651600 Vaccines
Procedure type	Open procedure (standard regime)
Legal basis	EU Directive 2014/24/EU
Total maximum value (EUR)	€31,521,600.00
Number of lots	32
Initial duration	12 months
Maximum renewals	3 (tacit renewal)
Maximum total duration	48 months
EU funding	None
Covered by GPA	Yes
Evaluation criteria	Price (70%), Quality (30%)
Location	Paris, France
Subcontracting	No

Lot Overview

The procurement is divided into 32 lots covering the following vaccines and tests:

Lot	Vaccine/Test	Max Value (€)	Winner(s)
1	Chikungunya (12+ years)	160,000	Bavarian Nordic France, Valneva France
2	Dengue	88,000	No winner (closed)
3	dTcaP (Diphtheria, Tetanus, Polio, Pertussis)	2,513,200	GSK, Sanofi
4	DTCaP (Diphtheria, Tetanus, Polio, Pertussis)	244,400	Sanofi
5	DTCaP + Hib	188,800	GSK
6	DTCaP + Hib + Hepatitis B	1,992,000	MSD France, GSK, Sanofi
7	Tick-borne encephalitis (12+ years)	8,000	Bavarian Nordic France
8	Japanese encephalitis	136,000	No winner (closed)
9	Yellow fever	515,200	Sanofi
10	High-dose quadrivalent influenza	96,000	No winner (closed)
11	Seasonal influenza tetravalent (6+ months)	683,600	Sanofi
12	Haemophilus influenzae b	10,000	Sanofi
13	Hepatitis A (16+ years)	384,000	GSK
14	Hepatitis A (up to 16 years)	373,200	GSK
15	Hepatitis B (16+ years)	989,600	GSK
16	Hepatitis B (up to 16 years)	174,800	GSK, MSD France
17	HPV nonavalent (types 6,11,16,18,31,33,45,52,58)	6,998,400	MSD France
18	Rotavirus monovalent (6+ weeks)	960,400	GSK
19	Leptospirosis	619,200	Imaxio
20	Meningococcal ACWY (12+ months) – single-use vial	1,157,600	Sanofi
21	Meningococcal B (2+ months)	7,027,200	GSK
22	Pneumococcal (15 serotypes)	3,824,800	MSD France
23	Pneumococcal (20 serotypes)	548,000	Pfizer
24	Rabies	158,800	Bavarian Nordic France, Sanofi
25	MMR (Measles, Mumps, Rubella – 9+ months)	784,000	MSD France, GSK
26	Tuberculin tests	28,800	No winner (closed)
27	BCG (Tuberculosis)	1,322,800	No winner (closed)
28	Typhoid (injectable)	98,800	Sanofi
29	Typhoid (oral, 5+ years)	58,000	Bavarian Nordic France
30	Varicella (Chickenpox)	99,200	MSD France, GSK
31	RSV (Respiratory Syncytial Virus) – for pregnant women	638,400	Pfizer
32	Shingles (Zona)	312,000	GSK

Winners Summary

The following pharmaceutical companies were awarded contracts across various lots:

Supplier	Lots Won	Size
Sanofi Winthrop Industrie	3, 4, 6, 9, 11, 12, 20, 24, 28	SME
Laboratoire GlaxoSmithKline (GSK)	3, 5, 6, 13, 14, 15, 16, 18, 21, 25, 30, 32	SME
MSD France	6, 16, 17, 22, 25, 30	SME
Pfizer	23, 31	SME
Bavarian Nordic France	1, 7, 24, 29	SME
Valneva France	1	SME
Imaxio	19	SME

Evaluation Criteria

All lots use the same evaluation criteria:

• Price (70%): Evaluated based on the estimated detail (détail estimatif)
• Quality (30%): Quality of the service (Qualité de la prestation)

About the Contracting Authority

VILLE de PARIS - DFA - SDA is the City of Paris's Directorate of Finance and Procurement (Direction des Finances et des Achats) - Procurement Sub-Directorate (Sous-direction des Achats). The authority is responsible for public procurement for the City of Paris, including healthcare-related supplies.

Procurement Analysis

• Procedure: Open procedure under the standard regime, governed by EU Directive 2014/24/EU.
• Competition: Strong competition across most lots, with 1-3 bidders per lot.
• SME participation: All winners are classified as SMEs (micro, small, or medium enterprises).
• No subcontracting: No subcontracting was declared by any winner.
• No EU funding: The procurement is not financed with EU funds.
• No framework agreement with reopening: The framework is without reopening of competition.
• No dynamic purchasing system used.
• Accelerated procedure: No.
• Review body: Tribunal Administratif de Paris.
• Lots without winners: Lots 2 (Dengue), 8 (Japanese encephalitis), 10 (High-dose influenza), 26 (Tuberculin tests), and 27 (BCG) received no tenders.

Additional Procurement Facts

• The contract is covered by the WTO's Government Procurement Agreement (GPA).
• No EU funds were used for this procurement.
• The framework agreements have no minimum commitment.
• All winners are French-registered pharmaceutical companies.
• The contracts are tacitly renewable up to 3 times (12 months each).
• Multi-supplier frameworks allow the City to source from multiple suppliers.
• Unit-price agreements ensure price transparency.
• Contracts are executed via purchase orders as needs arise.
• Lot 17 (HPV vaccine) is the largest lot at €6,998,400.
• Lot 21 (Meningococcal B) is the second largest at €7,027,200.

Market & Industry Perspective

The French vaccine market is dominated by a few major pharmaceutical companies, with strong competition for public sector contracts. The City of Paris, as one of France's largest public health authorities, has significant purchasing power.

Key trends in this market include:

• Public health focus: Strong investment in immunisation programmes
• Price competition: Price accounts for 70% of evaluation
• Multi-supplier frameworks: Ensuring supply security
• SME participation: SMEs compete effectively in the vaccine market
• Tacit renewals: Long-term contracts with automatic renewal

Economic Significance

At €31.5 million, this procurement represents a significant investment in public health for the City of Paris. The contracts will:

• Support public health: Ensure vaccine availability for Paris residents
• Enable immunisation: Support vaccination programmes
• Support SMEs: All winners are SMEs
• Provide long-term stability: Up to 4-year framework agreements
• Ensure supply security: Multi-supplier frameworks

Future Procurement Opportunities

With these frameworks now in place, future opportunities include:

• Re-tender: Expected after the 4-year maximum duration
• Additional vaccines: New vaccines entering the market
• Related supplies: Other pharmaceutical and medical supplies
• Other French cities: Similar vaccine procurements in other municipalities

Opportunities for Suppliers

While these contracts are awarded, opportunities remain for pharmaceutical suppliers:

• Re-tender: Prepare for the next procurement cycle
• New vaccines: Emerging vaccines not yet covered
• Other French cities: Similar opportunities in other municipalities
• Hospital sector: Vaccine procurements for public hospitals

What Businesses Should Watch

• City of Paris's future procurement notices
• Other French municipal vaccine tenders
• New vaccine approvals and market entries
• French public health procurement regulations
• Changes to immunisation programmes

FranceTenders Procurement Intelligence

This vaccine framework procurement is a notable example of French municipal healthcare procurement. Several features stand out:

• Scale: €31.5 million across 32 lots
• Comprehensive coverage: 31 vaccines and tuberculin tests
• Multi-supplier: Multiple suppliers per lot where applicable
• Price focus: 70% weighting on price
• SME participation: All winners are SMEs
• Tacit renewals: Up to 4-year contracts

For suppliers, this procurement highlights the importance of:

• Competitive pricing: Price accounts for 70% of evaluation
• Quality demonstration: Quality accounts for 30%
• Product portfolio: Wide range of vaccines in portfolio
• Supply reliability: Ability to supply Paris-wide
• SME status: SMEs can compete effectively

Supplier Takeaways

• Offer competitive pricing – 70% of evaluation is price-based
• Demonstrate quality – 30% weighting
• Maintain a diverse vaccine portfolio
• Ensure reliable supply chain for public health contracts
• Monitor French municipal vaccine procurement opportunities
• Consider SME status as an advantage

Key Takeaways

• City of Paris awarded vaccine framework contracts worth €31.5M
• 32 lots covering 31 vaccines and tuberculin tests
• Winners: Sanofi, GSK, MSD, Pfizer, Bavarian Nordic, Valneva, Imaxio
• Evaluation: Price (70%), Quality (30%)
• Duration: 12 months + up to 3 tacit renewals (max 48 months)
• All winners are SMEs
• 5 lots received no tenders
• Largest lots: HPV vaccine (€7M) and Meningococcal B (€7M)

Conclusion

This vaccine framework procurement ensures that the City of Paris has a reliable and diverse supply of vaccines and tuberculin tests for its public health programmes. By awarding contracts to multiple pharmaceutical companies across 32 lots, the City secures supply diversity and competitive pricing.

The 70% weighting on price reflects the importance of cost-effectiveness in public health procurement, while the 30% quality weighting ensures that service quality is not compromised. The participation of all SME winners demonstrates the accessibility of public procurement to smaller pharmaceutical companies.

For suppliers, this procurement highlights the importance of competitive pricing, quality demonstration, and a diverse product portfolio in winning public sector vaccine contracts.

Frequently Asked Questions

Q: What is the City of Paris?

Ans: The local authority for Paris, France's capital city, responsible for public services including public health.

Q: What is the total value of the procurement?

Ans: €31,521,600 maximum across all 32 lots.

Q: Who are the winners?

Ans: Sanofi Winthrop Industrie, Laboratoire GlaxoSmithKline (GSK), MSD France, Pfizer, Bavarian Nordic France, Valneva France, and Imaxio.

Q: What vaccines are covered?

Ans: Chikungunya, dengue, diphtheria-tetanus-polio-pertussis (various combinations), hepatitis A/B, HPV, meningococcal, pneumococcal, rabies, influenza, rotavirus, typhoid, varicella, RSV, shingles, MMR, BCG, and others.

Q: What were the evaluation criteria?

Ans: Price (70%) and Quality (30%).

Q: How long are the contracts?

Ans: 12 months initial, with up to 3 tacit renewals (maximum 48 months).

Q: How many lots were awarded?

Ans: 32 lots in total, with 5 lots receiving no tenders.

Q: Is this contract funded by the EU?

Ans: No, the procurement is not financed with EU funds.

Q: What is the review body?

Ans: Tribunal Administratif de Paris.

Source: EU Official Journal, Contract Award Notice 588685-2026, OJ S 164/2026, published 26 August 2026.